You are here

Mide Kanserinde Prognostik Faktörler

Prognostic Factors in Gastric Cancer

Journal Name:

Publication Year:

Abstract (2. Language): 
Aim: To identify the prognostic factors of the gastric cancer cases that had been operated in our department. Materials and Method: The record of 81 patients out of 363 gastric cancer patients, who had been performed the curative resection between January 1990 - December.2000, were retrospectively reviewed. Age, gender, initial symptoms, type of surgery, additive organ resections, postoperative complications, tumor lacalization, tumor size, macroscopic type of the tumor, tumor histologic type, depth of invasion, number of dissected lymph nodes, number of metastatic lymph nodes and the effects of prognostic factors on survival were investigated. Results: Of the 81 patients, 51 were men and 30 were women and the mean age was 57.8 (24-77) years. Age had no significant effect on survival. The univariant analysis of the examined factors showed that;proximal location and diffuse involvement(p=0.005), tumor size larger than 10 cm (p=0.002), macroscopic type of the tumor(bormann type IV) (p=0.008), depth of invasion (p=0.024), number of metastatic lymph nodes larger than 6 (p=0.026), TNM classification(stage IIIB) (p=0.035) were the factors affecting survival. Multivariant Cox regression analysis revealed that number of metastatic lymph nodes, the ratio of the metastatic nodes to the total number of nodes, TNM were independent predictors of survival. Conclusion: In this study, number of metastatic lymph nodes, the ratio of the metastatic nodes to the total number of nodes, TNM were found as independent predictors of survival. However, our case number was not enough make such a definite interpretation about the effect of the gastric wall invasion and lymphadenectomy on survival, Thefefore, the number of the early cases should incerase, and also the surgical procedure should be standardized.
Abstract (Original Language): 
Amaç: Mide kanseri nedeniyle ameliyat ettiğimiz hastalarda prognostik faktörlerin belirlenmesi. Gereç ve Yöntem: Ocak 1990-Aralık 2000 yılları arasında mide kanseri nedeniyle opere edilen 363 hastadan 15’in üzerinde lenf bezi çıkarılan, küratif rezeksiyon uygulanan 81 hastanın kayıtları retrospektif olarak incelendi.Yaş, cinsiyet, başvuru semptomları, uygulanan ameliyat şekli, ameliyata eklenen diğer organ rezeksiyonları, postoperatif komplikasyonlar, tümör yerleşim yeri, tümör boyutu, tümör makroskopik tipi, tümör histolojik tipi, invazyon derinliği, toplam çıkarılan lenf nodu sayıları, metastatik lenf nodu sayıları sınıflamasının prognostik faktör olarak sağkalıma etkisine bakıldı. Bulgular: Hastaların 51’i erkek, 30’u kadın ve yaş ortalamaları 57.8 (24-77) idi. Hastaların verileri univaryans analizle incelendiğinde; proksimal lokalizasyonu ve diffüz yayılım(p=0.005), tümör boyutunun 10 cm’den büyük olması (p=0.002), tümör makroskopik tipi(borrman tip IV) (p=0.008), invazyon derinliği (p=0.024), metastatik lenf nodu sayısının 6’dan büyük olması (p=0.026) ve TNM sınıflamasının(evre IIIB) (p=0.035) sağkalıma etkisi olduğu görüldü. Bu faktörler multivaryans Cox regresyon analiziyle incelendiğinde metastatik lenf nodu sayısı, metastatik lenf nodunun toplam çıkarılan lenf noduna oranının ve TNM sınıflamasının bağımsız prognostik faktörler olduğu saptandı. Sonuç: Çalışmamızda metastatik lenf nodu sayısı, metastatik lenf nodu sayısının çıkarılan toplam lenf nodu sayısına oranı ve TNM sınıflaması bağımsız prognostik faktörler olarak bulunmuştur. Ancak duvar invazyonu ve lenfadenektominin sağkalıma etkisini daha net ortaya koyabilmemiz için vaka serimizin ve erken evre hastalarımızın sayısının artmasına ve cerrahi tekniğin standardizasyonuna ihtiyaç vardır.
113-118

REFERENCES

References: 

1. Bozzetti F, Marubini E, Bonfanti G,. Subtotal versus total
gastrectomy for gastric cancer: Five_years survival rates in a
multicenter randomized Italian trial. Italian Gastrointestinal
Tumor Study Group. Ann Surg 1999;230:170-8.
2. Kim JP, Lee JH, Kim SJ, Yu HJ, Yank HK. Clinicopathologic
characteristics and prognostic factors in 10783 patients with
gastric cancer. Gastric Cancer 1998;1:125-33.
3. Dicken BJ,Bigam DL; Cass C, Mackey JR, Joy AA; Hamilton
SM. Gastric adenocarcinoma. Ann Surg 2005;241:27-39.
4. Göçmen E, Kocaoğlu H. Mide kanseri epidemiyolojisi. Türkiye Klinikleri Cerrahi Dergisi. 2000;5:161-2.
5. Gore R. Gastrointestinal cancer. Radiol Clin North Am,
1997;35:295-310.
6. Lavecchia C, Negri E, Fraceschi S. Family history and the risk
of stomach and colorectal cancer. Cancer 1992;70:50-5.
7. Jatre JP, Meyer HJ. Total gastrectomy in the surgical
treatment of primary gastric adenocarcinoma- a 30 year single
instution experience. Hepatogastroenterology 2001;48:1222-6.
8. Harrison JP, Fielding JWL prognostic factors for gastric
cancer, influencing clinical practice. World J Surg
1995;16:496-500. S.B. Akyağcı, ark.
118
9. Boku T, Nakare Y, Minovra T. Prognostic significance of
serosal invasion and free intraperitoneal cancer cells in gastric
cancer. Br J Surg 1990 ; 77: 436-7.
10. Msika S, Chastong C, houry S, Lacaine F, Huguier M. Lymph
node involvement as the only prognostic factor in curative
resected gastric carcinoma: A multivariate analysis. Word J
Surg 1989;13:118-23.
11. Siewert JR, Böttcher K, Stein JH, Roder DJ. Relevant
prognostic factors in gastric cancer ten years result of the
German Gastric Cancer Study. Ann Surg 1998;228:449-461.
12. Yu CCW, Levison DA, Dunn JA, Ward LC, Demonakau M,
Allum WH. Pathological prognostic factors in the second
British Stomach Cancer Group trial of adjuvant therapy in
resectable gastric cancer. Br J Cancer 1995;71:1106-10.
13. Nakamura K, Ueyama T, Yan T, Xvan ZX, Ambe K, Adachi
Y. Pathology and prognosis of gastric carcinoma. Finding in
1000 patients who underwent primary gastrectomy. Cancer
1999;70:1030-7.
14. Santiago JMR, Muroz E, Marti M, Quintana S, Velosa E,
Marco C. Metastatic lymph node ratio as a prognostic factor in
gastric cancer. EJSO, 2005;31:59-66.
15. Machara Y, Watarabe A, Kakeji Y, emi Y, Mariguchi S, Arai
H. Prognosis for surgically treated gastric cancer patients is
poorer for women than man in all patients under age 50. Br J
Cancer 1992;65:417-20.
16. Bueno FS, Marcilla JAG, Flores DP; Abad JMP, Vicente R;
Aranda F, Ramirez P, Parilla P. Prognostic factors in a series
of 297 patients with gastric adenocarcinoma undergoing
surgical resection. Br J Surg 1998;85:255-60.
17. Persiani R, D’ugo D, Rausei S, Sermoneta D, Borene C,
Pozzo C, Ricci R, Torre GL, Picciocchi A. Prognostic
indicators in locally advanced gastric cancer treated with
preoperative chemotherapy and D2 gastrectomy. J Surg Oncol
2005;89:227-36.
18. Kim TH, Han SU; Cho YK. Perigastric lymh node status can
be a simple prognostic parameter in patients with gastric
cancer. Hepatogastroenterology 2000;47:1485-8.
19. Talamanti MS, Kim SP, Yao KA; Wayne JD, Feinglass J,
Bennett CC; Rao S. Surgical autcomes of patients with gastric
carcinoma:the importance of primary tumor location and
microvessel invasion. Surgery 2003;134:720-7.
20. Adachi Y; Shiraishi N, Suematsu T. Most important lymph
node information in gastric cancer: multivariate prognostic
study. Ann Surg Oncol 2000;7:503-7.
21. Nakamura K, Ueyama T, Yao T. Pathology and prognosis of
gastric carcinoma. Cancer 1992;70:1030-7.
22. Ding YB, Chen GY, Xia JG, Zang XW, Yang HY, Yang L,
Liu YX. Correlation of tumor-positive ratio and number of
perigastric lymph nodes with prognosis of gastric carcinoma
in surgically treated patients.Word J Gastroenterol
2004;10:182-5.
23. Inoue K, Nakane Y, Liyama H, Sato M, Kanbara T, Nakai K,
Okumura S, Yamamichi K, Hioki K. The superiority of ratio
based lymph node staging in gastric carcinoma. Ann Surg
Oncol 2001;9:27-34.
24. Bando E, Yonemura Y, Taniguchi K, Fushida S, Fujimura T,
Miwa K. Outcome of ratio of lymph node metastasis in gastric
carsinoma. Ann Surg Oncol 2002;9:775-84.
25. Maruyama K. The most important prognostic factors cancer
patients: a study using univariate and multivariate analyses.
Scand J Gastroenterol 1987;22:63-8.
26. Kim JP:surgical results in gastric cancer. Surg Oncol
1999;17:132-8.

Thank you for copying data from http://www.arastirmax.com